Publication | Closed Access

Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non–Small Cell Lung Cancer

MedicineImmunologyTumor ImmunityImmune Checkpoint InhibitorCancer TreatmentAssay SystemsPredictive PerformanceOncologyRadiation OncologyLung CancerNivolumab Response